CoChat
Sign Up
Cited by 434Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Mini-Special Issue paper Management of diabetic patients with hypoglycemic agents α-Glucosidase inhibitors and their use in clinical practice

Open access
Derosa, Giuseppe, Maffioli, Pamela·2012·Archives of Medical Science
DOI 10.5114/aoms.2012.31621PMC PMC3506243
Open this paper in CoChat — free accountOpen PDF

Abstract

Post-prandial hyperglycemia still remains a problem in the management of type 2 diabetes mellitus. Of all available anti-diabetic drugs, α-glucosidase inhibitors seem to be the most effective in reducing post-prandial hyperglycemia. We conducted a review analyzing the clinical efficacy and safety of α-glucosidase inhibitors, both alone and in combination with other anti-diabetic drugs, with respect to glycemic control, inflammation and atherosclerosis. α-Glucosidase inhibitors proved to be effective and safe both in monotherapy and as an add-on to other anti-diabetic drugs. Compared to miglitol and voglibose, acarbose seems to have some additive effects such as stabling carotid plaques, and reducing inflammation. Acarbose also proved to reverse impaired glucose tolerance to normal glucose tolerance.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5114/aoms.2012.31621

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 42

  1. [1]Athyros VG Gossios TD Tziomalos K Florentin M Karagiannis A Mikhailidis DP Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment? Arch Med Sci 2011 7 1067 75 22328892 PMC3265001
  2. [2]Aronow WS Editorial on management of diabetes mellitus with coronary artery disease Arch Med Sci 2011 7 928 30 22328872 PMC3264981
  3. [3]Rydén L Standl E Bartnik M Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 2007 28 88 136 17220161
  4. [4]American Diabetes Association Standards of medical care in diabetes: 2012 Diabetes Care 2012 35 Suppl 1 S11 63 22187469 PMC3632172
  5. [5]Derosa G Tinelli C Maffioli P Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes Diabetes Obes Metab 2009 11 1091 9 19765050
  6. [6]Derosa G Maffioli P GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy Curr Clin Pharmacol 2012 7 214 28 22432846
  7. [7]Derosa G Maffioli P Dipeptidyl peptidase-4 inhibitors: 3 years of experience Diabetes Technol Ther 2012 14 350 64 22324384
  8. [8]Shiraiwa T Kaneto H Miyatsuka T Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients Diabetes Care 2005 28 2806 7 16249562
  9. [9]DECODE Study Group, the European Diabetes Epidemiology Group Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria Arch Intern Med 2001 161 397 405 11176766
  10. [10]Bell DS O'Keefe JH Jellinger P Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 2008 14 112 24 18238751
  11. [11]Derosa G D'Angelo A Salvadeo SA Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects Microvasc Res 2010 79 144 9 20079360
  12. [12]Derosa G D'Angelo A Salvadeo SA Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients Horm Metab Res 2010 42 8 13 19735057
  13. [13]Derosa G Mereu R D'Angelo A Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin J Clin Pharm Ther 2010 35 565 79 20831680
  14. [14]Derosa G D'Angelo A Salvadeo SA Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment Biomed Pharmacother 2009 63 723 33 19906504
  15. [16]Dickersin K Scherer R Lefebvre C Identifying relevant studies for systematic reviews BMJ 1994 309 1286 91 7718048 PMC2541778
  16. [18]Puls W Pharmacology of glucosidase inhibitors Oral Antidiabetics. Springer, Berlin 1996 119 497 525
  17. [19]Krause HP Ahr HJ Kuhlmann J Puls W Pharmacokinetics and metabolism of glucosidase inhibitors Handbook of experimental pharmacology 1996 Springer, Berlin Oral Antidiabetics 541 5
  18. [20]Bischoff H Vasselli J Maggio C Scriabine A Pharmacology of alpha-glucosidase-inhibitors Drugs in development: alpha-glucosidase inhibition: potential use in diabetes 1993 Branford Neva Press 3 13
  19. [21]Göke B Fuder H Wieckhorst G Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve Digestion 1995 56 493 501 8536820
  20. [22]Standl E Schernthaner G Rybka J Hanefeld M Raptis SA Naditch L Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics Diabetes Res Clin Pract 2001 51 205 13 11269893
  21. [24]Piñol C Roze S Valentine W Evers T Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain Gac Sanit 2007 21 97 104 17419924
  22. [25]Roze S Valentine WJ Evers T Palmer AJ Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting Curr Med Res Opin 2006 22 1415 24 16834840
  23. [26]Neeser K Lübben G Siebert U Schramm W Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective Pharmacoeconomics 2004 22 321 41 15061682
  24. [27]Derosa G Salvadeo SA D'Angelo A Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial Curr Med Res Opin 2009 25 607 15 19232035
  25. [28]Kim MK Suk JH Kwon MJ Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes Diabetes Res Clin Pract 2011 92 322 8 21376417
  26. [29]Kimura T Suzuki J Ichikawa M Differential effects of alpha-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with Insulin Lispro Mix 50/50 Diabetes Technol Ther 2012 14 545 51 22519736
  27. [30]Mori Y Shiozaki M Matsuura K Tanaka T Yokoyama J Utsunomiya K Evaluation of efficacy of acarbose on glucose fluctuation and postprandial glucose using continuous glucose monitoring in type 2 diabetes mellitus Diabetes Technol Ther 2011 13 467 70 21355714
  28. [31]Wang JS Lin SD Lee WJ Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison Clin Ther 2011 33 1932 42 22078152
  29. [32]Lin SD Wang JS Hsu SR The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data J Diabetes Complications 2011 25 332 8 21813293
  30. [33]Derosa G Maffioli P D'Angelo A Fogari E Bianchi L Cicero AF Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study J Diabetes Complications 2011 25 258 66 21367625
  31. [34]Derosa G Maffioli P Ferrari I Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load Eur J Pharmacol 2011 651 240 50 21118681
  32. [35]Shimazu T Inami N Satoh D Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients J Thromb Thrombolysis 2009 28 429 35 19137265
  33. [36]Osonoi T Saito M Mochizuki K The alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus Metabolism 2010 59 1816 22 20667563
  34. [37]Emoto T Sawada T Hashimoto M Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease Am J Cardiol 2012 109 42 6 21944671
  35. [38]Fujitaka K Otani H Jo F Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome Endocr J 2011 58 425 32 21498915
  36. [39]Hirano M Nakamura T Obata JE Early improvement in carotid plaque echogenicity by acarbose in patients with acute coronary syndromes Circ J 2012 76 1452 60 22453003
  37. [40]Koyasu M Ishii H Watarai M Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease Clin Ther 2010 32 1610 7 20974318
  38. [41]Kataoka Y Yasuda S Miyamoto Y DIANA study investigators. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients Circ J 2012 76 712 20 22240597
  39. [42]Kawamori R Tajima N Iwamoto Y Kashiwagi A Shimamoto K Kaku K Alpha-glucosidase inhibitor for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance Nihon Rinsho 2009 67 1821 5 19768922
  40. [43]Chiasson JL Josse RG Gomis R STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial Lancet 2002 359 2072 7 12086760
  41. [44]Chiasson JL Josse RG Gomis R STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 2003 290 486 94 12876091
  42. [45]Zarich SW Nesto RW Implications and treatment of acute hyperglycemia in the setting of acute myocardial infarction Circulation 2007 115 e436 9 17485582

Cited by

Sorted by citations

Authors
Derosa, G., & Maffioli, P.
Affiliations
University of Pavia (IT)
Corresponding author
Derosa, Giuseppe
ORCID
Venue
Archives of Medical Science
Publisher
Termedia Sp. z.o.o.
Published
2012
Volume
5
Issue
5
Pages
899-906
ISSN
1734-1922 (ISSN-L)
DOI
10.5114/aoms.2012.31621
PMC
PMC3506243
OpenAlex
W128376936
Cited by
434
References
1
Citations by year
2026: 32 · 2025: 45 · 2024: 51 · 2023: 48 · 2022: 60 · 2021: 36 · 2020: 30 · 2019: 22 · 2018: 24 · 2017: 19 · 2016: 20 · 2015: 19 · 2014: 18 · 2013: 9
FWCI
11.81
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Archives of Medical Science (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
alpha-glucosidase inhibitors, type 2 diabetes, postprandial hyperglycemia, acarbose, miglitol, voglibose, glycemic control, inflammation, atherosclerosis, impaired glucose tolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review